智翔金泰：GR1802注射液青少年季节性过敏性鼻炎适应症获得药物临床试验批准通知书

Core Viewpoint - The company, Zhixiang Jintai (688443.SH), has received approval from the National Medical Products Administration for the clinical trial of GR1802 injection for adolescent seasonal allergic rhinitis [1] Group 1: Company Developments - GR1802 injection is a recombinant fully human anti-IL-4Rα monoclonal antibody developed independently by the company [1] - The company has previously obtained clinical trial approval notifications for multiple indications for GR1802 injection [1] Group 2: Regulatory and Market Implications - Following the completion of clinical trials, the company must submit a new drug application and obtain a drug registration certificate before the product can be marketed [1]